Maharashtra, India -- (SBWire) -- 09/05/2018 --DTaP and Tdap Market
Summary

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment.

Browse More Detail Information of Report at https://www.reportsmonitor.com/request_sample/95204 

The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF's total procurement.

Major Players in DTaP and Tdap market are: Sanofi Pasteur,GlaxoSmithKline,Protein Sciences Corporation,Novartis AG,Seqirus,Merck Sharp & Dohme Corp,Astellas Pharma US, Inc,Pfizer Inc,Johnson & Johnson,Lanzhou Institute of Biological Products Co., Ltd,AstraZeneca,Emergent BioSolutions Inc.

Major Regions play vital role in DTaP and Tdap market are: North America (United States, Canada and Mexico),Europe (Germany, France, UK, Russia and Italy),Asia-Pacific (China, Japan, Korea, India and Southeast Asia),South America (Brazil, Argentina, Colombia etc.),Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Check Discount for this Report @ https://www.reportsmonitor.com/check_discount/95204 

Research Framework

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. T

he Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market.

In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

Scope of the Report: 

Global DTaP and Tdap Market: Type Outlook: DTaP,Td,Tdap.

Global DTaP and Tdap Market: Application Outlook: Adult,Pediatric.

Reasons to Buy:


- Envision the composition of the DTaP and TdapMarket, in terms of the different applications of the (market name), underlining the major industry resources and players.

- Examine the product pipeline and study by stage of the disease, molecule target, with a granulated breakdown across key symptoms.

- Understand the growth with respect to the (market name) and market revenue for the market globally and across the key players and market segments.

- Study the market in terms of the generic and premium product revenue.

- Determine commercial opportunities in the DTaP and TdapMarket sales scenario by analyzing trends in authorizing and co-development deals.


Read Detailed Report @ https://www.reportsmonitor.com/report/95204/DTaP-and-Tdap-Vaccines-Market 

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.